{"schema_version":"secwatch.filing_event.v1","accession":"0001818382-22-000103","form_type":"8-K","ticker":"HUMA","cik":"0001818382","company_name":"Humacyte, Inc.","filed_at":"2022-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.190478+00:00","generated_at":"2026-06-24T00:27:42.373042+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Humacyte Q2 net income $36.9M driven by non-cash gains; HAVs show promise in Ukraine","bullets":["Cash $189.0M as of June 30, 2022; company expects runway through 2024, past potential HAV approval in vascular trauma.","Net income $36.9M vs net loss $17.2M in Q2 2021; driven by $55.4M non-cash gain from contingent earnout remeasurement.","Revenue $1.3M (grants), up from $0.7M; R&D expense $14.7M, G&A $5.2M.","HAVs implanted in Ukraine under humanitarian initiative reportedly functioning and infection-free, saving limbs.","Appointed Diane Seimetz to Board and Shamik Parikh as CMO; preclinical small-diameter HAV data in CABG presented."],"urls":{"canonical":"https://secwatch.observer/filing/0001818382-22-000103","json":"https://secwatch.observer/filing/0001818382-22-000103.json","markdown":"https://secwatch.observer/filing/0001818382-22-000103.md","text":"https://secwatch.observer/filing/0001818382-22-000103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818382/000181838222000103/0001818382-22-000103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818382/000181838222000103/huma-20220812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:27:42.373042+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}